Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Operating Expenses (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Operating Expenses data on record, last reported at $24.0 million in Q4 2025.

  • For Q4 2025, Operating Expenses fell 77.93% year-over-year to $24.0 million; the TTM value through Dec 2025 reached $84.2 million, down 47.59%, while the annual FY2025 figure was $84.2 million, 47.59% down from the prior year.
  • Operating Expenses reached $24.0 million in Q4 2025 per ACRS's latest filing, up from $20.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $108.9 million in Q4 2024 and bottomed at $14.8 million in Q3 2024.
  • Average Operating Expenses over 5 years is $29.5 million, with a median of $22.2 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: surged 403.71% in 2024, then crashed 77.93% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $24.4 million in 2021, then skyrocketed by 50.99% to $36.8 million in 2022, then plummeted by 41.31% to $21.6 million in 2023, then soared by 403.71% to $108.9 million in 2024, then plummeted by 77.93% to $24.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $24.0 million in Q4 2025, $20.4 million in Q3 2025, and $20.2 million in Q2 2025.